**BREAST CANCER**

NRG - BR003 Doxorubicin Hydrochloride and Cyclophosphamide followed by Paclitaxel with or without Carboplatin in Treating Patients with Triple-Negative Breast Cancer

S1418/BR006 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor Negative BC with >1cm Residual Invasive Cancer or Positive Nodes after Neo-Adj Chemo

A011401 (BWEL) Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Stage Breast Cancer

A011502 (ABC Trial) A Randomized Phase III Double-Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive, HeR2 Negative Breast Cancer

S1207 Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer

GCC-1366 A prospective study of neoadjuvant non-steroidal aromatase inhibitors in postmenopausal women with operable hormone receptor-positive breast cancer to evaluate the anti-proliferative response in obese and overweight patients

S1501 Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer

**COLORECTAL CANCER**

S0820 Adenoma and Second Primary Prevention Trial (PACES). A double-blinded trial of Eflornithine and Sulindac.

**GYN CANCER**

NRG-GY005 (ON HOLD BY STUDY SPONSOR) Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

**LUNG CANCER**

A151216 (Alchemist Screening Trial) Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Lung Cancer that has been or will be removed by Surgery

A081105 (Alchemist Treatment Trial) Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-Small Cell Lung Cancer that has been completely removed by Surgery
E4512 (Alchemist Treatment Trial) Crizotinib in Treating patients with Stage IB-IIA Non-Small Cell Lung Cancer that has been removed by Surgery and ALK Fusion Mutations

EAS142 (Alchemist Treatment Trial) Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

S1400 (LUNG-MAP) A biomarker-driven master protocol for previously treated Squamous Cell Lung Cancer. Targeted Treatment for Advanced Squamous Cell Cancer

S1400I (Lung-MAP Sub-Study) A Phase III Randomized Study of Nivolumab Plus Ipilimumab versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker

S1400G (Lung-MAP Sub-Study) A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer

A211401 Smoking Cessation Prior to Surgery to Reduce Surgical Complications

ADAPTIMMUNE A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies

NHLBI-MDS Suspected MDS or MDS/MPN Overlap Disorders or Pathologic diagnosis of MDS in 6 mos. Prior to enrollment and untreated.

REPOSITORY: MULTI-SITE TISSUE BANKING

AST-FPB-US (ASTERAND) A Multi-Center Study for the Collection of Surplus Surgical Tissues for Genomics, Proteomics and Biomarker Research (Fresh, Preserved, Biofluid)

QUALITY OF LIFE STUDIES

MARYLAND LIVING WELL, CANCER: THRIVING AND SURVIVING QOL RESEARCH: Maryland Department on Aging, Maryland Department of Health and Mental Hygiene